10q10k10q10k.net
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.DAWNEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing targeted precision oncology therapies for pediatric and young adult patients with genetically driven cancers. It advances novel drug candidates to address unmet medical needs in underserved patient segments, operating primarily in the U.S. and partnering with global oncology research institutions.

Q3 2025Q2 2025Q1 2025Q3 2024Q1 2024Q3 2023

Revenue

$30.8M

Gross Profit

N/A

Operating Profit

$-41.1M

Net Profit

$-36.0M

Gross Margin

N/A

Operating Margin

-133.5%

Net Margin

-117.0%

YoY Growth

N/A

EPS

$-0.35

Day One Biopharmaceuticals, Inc. Q1 FY2025 Financial Summary

Day One Biopharmaceuticals, Inc. reported revenue of $30.8M for Q1 FY2025, with a net profit of $-36.0M (up 42.3% YoY) (-117.0% margin).

Key Financial Metrics

Total Revenue$30.8M
Net Profit$-36.0M
Gross MarginN/A
Operating Margin-133.5%
Report PeriodQ1 FY2025

Day One Biopharmaceuticals, Inc. Quarterly Revenue & Net Profit History

Day One Biopharmaceuticals, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q3 FY2025$39.8M-57.6%$-19.7M-49.6%
Q2 FY2025$33.9M+313.9%$-30.3M-89.4%
Q1 FY2025$30.8M—$-36.0M-117.0%
Q3 FY2024$93.8M—$37.0M39.5%
Q1 FY2024$0—$-62.4MN/A
Q3 FY2023$0—$-46.1MN/A

Income Statement

Q3 2023Q1 2024Q3 2024Q1 2025Q2 2025Q3 2025
Revenue$0$0$93.8M$30.8M$33.9M$39.8M
YoY GrowthN/AN/AN/AN/A313.9%-57.6%

Balance Sheet

Q3 2023Q1 2024Q3 2024Q1 2025Q2 2025Q3 2025
Assets$414.2M$326.6M$600.8M$534.4M$519.0M$513.8M
Liabilities$24.6M$29.8M$45.3M$54.8M$58.2M$62.9M
Equity$389.6M$296.8M$555.5M$479.5M$460.8M$450.9M

Cash Flow

Q3 2023Q1 2024Q3 2024Q1 2025Q2 2025Q3 2025
Operating CF$-37.1M$-49.7M$50.8M$-59.0M$-24.8M$-5.8M